RWJBarnabas Health and Rutgers Cancer Institute of New Jersey | Strategic Alliance Partners

May 20, 2022

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

May 13, 2022

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

May 12, 2022

With the aid of a $3.5 million National Institutes of Health grant, investigators from Rutgers Cancer Institute of New Jersey, along with Holden Cancer Center at the University of Iowa, and the University of Texas MD Anderson Cancer Center, are collaborating on a project to address lung cancer screening disparities among individuals with a history of heavy smoking

April 01, 2022

Mridula George, MD, discusses efforts to address unmet needs in HER2-low breast cancer.

February 16, 2022

Rutgers Cancer Institute of New Jersey has named Sanjay Goel, MD, MS as director of its Phase I/Investigational Therapeutics Program.

February 10, 2022

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

January 12, 2022

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

December 31, 2021

Despite advances in treatments for T-cell acute lymphoblastic leukemia, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of the disease, as well as the need to discover new targeted therapeutic approaches and treatment resistance

December 28, 2021

Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.

December 17, 2021

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

December 16, 2021

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.

December 13, 2021

Physician-scientists from Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, will present expansive new hematology/oncology data from their clinical research program at the 2021 ASH Annual Meeting and Exposition.

December 07, 2021

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

December 06, 2021

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

December 02, 2021

Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.

December 01, 2021

Researchers from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in tumor sequencing assays to predict the origin of detected DNA alterations.

November 23, 2021

Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

November 23, 2021

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

November 23, 2021

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

November 22, 2021

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.